Serum metabolism during breast cancer treatment.

• DOI: 10.1200/jco.2017.35.15_suppl.e23043
• Publication Date: 2018-09-06T15:58:12Z
• Authors: Guro Fanneløb Gis...; Torfinn Støve Mad...; Riyas Vettukattil; Vidar Gordon Flote; Anders Husøy; Trygve Lofterød; Steinar Lundgren; Gro Falkener Bert...; Ellen Schlichting; Erik Andreas Wist; Inger Thune; Tone Frost Bathen
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e23043 Serum metabolism during breast cancer treatment Background: Breast may include surgery, systemic therapy and radiation, often involving side-effects. Many patients experience weight gain treatment, which is associated with decreased survival rates 1 . The purpose of this study was to describe serum metabolic alterations in undergoing relate these treatment. Methods: This pilot includes 60 patients, aged 35-75 years, histologically verified stage I/II disease. All underwent tumor were treated according national guidelines. Samples collected before 6 months after analyzed by MR spectroscopy (MRS) mass spectrometry (MS). 170 metabolites 105 lipoprotein subfractions quantified combined MRS MS analyses. Results: Multilevel PLS-DA showed significant metabolite profiles post-treatment, both receiving (n = 35) not 25) chemotherapy (classification accuracy: 86.7% 77.0%, resp., p < 0.001). Lipoprotein also significantly altered groups (p Chemotherapy recipients had levels citrate, ornithine, methionine while non-recipients increased glutamate, alanine, proline two biogenic amines, acylcarnitines. 17/52 (32.7%) gained (≥ 1.5 kg) Weight predicted from pre-treatment samples accuracy 67.0% 0.020). lower three acylcarnitines 20 phosphocholines, higher lysine isoleucine, suggesting aberrant lipid amino acid metabolism. reflected the post-treatment (accuracy 66.8%, 0.015), having five acylcarnitines, glycine, isoleucine valine. Conclusions: indicates that induces changes levels. Patients gaining different than those 1. Chan et al, Ann Oncol 25: 1901-14, 2014.